Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000827134
Ethics application status
Approved
Date submitted
24/05/2019
Date registered
7/06/2019
Date last updated
5/11/2020
Date data sharing statement initially provided
7/06/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Telephone-delivered adherence therapy for adults with type 2 diabetes: a feasibility study
Query!
Scientific title
Telephone-delivered adherence therapy for adults with type 2 diabetes: a feasibility study
Query!
Secondary ID [1]
298225
0
None
Query!
Universal Trial Number (UTN)
U1111-1233-6390
Query!
Trial acronym
ATT2D (Adherence Therapy for patients with Type 2 Diabetes)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 diabetes
312826
0
Query!
Condition category
Condition code
Metabolic and Endocrine
311326
311326
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Adherence therapy (AT) is a brief psychological intervention based on the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT). AT is a patient-centred approach delivered by a trained clinician over a series of 8 sessions weekly. Each session will take about half an hour. Key therapy techniques include adherence assessment (session 1) medication problem solving (session 2 and 3), exchanging information (session 4), exploring ambivalence (session 5 and 6), and challenging beliefs (session 7 and 8). Theoretically, these techniques amplify the personally relevant benefits of treatment, modify illness and treatment beliefs, and resolve ambivalence towards taking medication. The intervention will be delivered over the telephone. Treatment fidelity will be checked by an independent rater against an AT scale using audio recordings of a random selection of sessions (approximately 4).
Query!
Intervention code [1]
314469
0
Behaviour
Query!
Comparator / control treatment
Participants in the control and experimental group will continue receiving their usual care. Treatment as usual for adults with type two diabetes includes regular doctor visits and meetings with the health educator if referred by the doctor. Meetings with the diabetes educator include reviewing patient’s glycaemic control tests, glucose monitoring, and a didactic educational session.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
320056
0
The number of patients that need to be asked to get one to provide written informed consent. Data will be extracted from study records.
Query!
Assessment method [1]
320056
0
Query!
Timepoint [1]
320056
0
Two days after receiving the participant information sheet and informed consent.
Query!
Primary outcome [2]
320116
0
The number of participants who complete the therapy.
Data will be extracted from study records.
Query!
Assessment method [2]
320116
0
Query!
Timepoint [2]
320116
0
Eight weeks after the first day of the therapy.
Query!
Primary outcome [3]
320117
0
The number of participants who complete the baseline and follow up assessments.
Data will be extracted from study records.
Query!
Assessment method [3]
320117
0
Query!
Timepoint [3]
320117
0
Baseline assessments: within two weeks of participants giving consent.
Follow-up assessments: nine weeks after completion of the baseline assessments.
Query!
Secondary outcome [1]
370382
0
The number of patients asked about taking part in the study who express interest and request participant information sheet.
Data will be extracted from study records.
Query!
Assessment method [1]
370382
0
Query!
Timepoint [1]
370382
0
In the first week when patients are approached about participating in the study.
Query!
Secondary outcome [2]
370661
0
The number of patients who meet the inclusion criteria.
Data will be extracted from study records.
Query!
Assessment method [2]
370661
0
Query!
Timepoint [2]
370661
0
In order to determine if participants are non-adherent and meet study inclusion criteria, subjects will be asked to complete the Medication Adherence Rating Scale at the screening visit. We will only include non-adherent patients (defined as a Medication Adherence Rating Scale score less than or equal to 5).
Query!
Secondary outcome [3]
370662
0
Adherence determined using the Medication Adherence Rating Scale.
Query!
Assessment method [3]
370662
0
Query!
Timepoint [3]
370662
0
At baseline and weeks nine after completion of treatment.
Query!
Secondary outcome [4]
370663
0
Patient beliefs about medication will be determined using the Beliefs about medication Questionnaire.
Query!
Assessment method [4]
370663
0
Query!
Timepoint [4]
370663
0
At baseline and weeks nine after completion of treatment.
Query!
Eligibility
Key inclusion criteria
• Adults aged 18 and over
• Diagnosed with type two diabetes for at least 1 year.
• Prescribed with a combination of diabetes medications
• Non-adherent according to medication adherence rating (score<=7)
• Participants that have access to a telephone
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Participating in other clinical trials
• Currently receiving any other psychological or psychosocial intervention
• Patients with a terminal illness, brain injury, psychosis, dementia, cognitive impairment, or memory problem as these conditions might make it difficult for patients to engage in treatment.
• Hearing impaired, as the program is delivered via phone and required the participants to communicate verbally.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
We will use sealedenvelope.com to randomize participants. This is a third party randomization service that is independent of the research team.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated random sequence generation. Permuted blocks of between 4, 6 and 8.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
We will use descriptive statistics to summarise the number and proportion of patients who complete each point of the trial. Summary statistics (means, proportions, 95% confidence intervals) will be tabulated for outcome variables but we do not intend to undertake any form of statistical analysis.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/01/2020
Query!
Actual
1/07/2020
Query!
Date of last participant enrolment
Anticipated
1/02/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
30/04/2021
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
7
Query!
Final
Query!
Recruitment outside Australia
Country [1]
21475
0
Saudi Arabia
Query!
State/province [1]
21475
0
Riyadh
Query!
Funding & Sponsors
Funding source category [1]
302766
0
Government body
Query!
Name [1]
302766
0
Saudi Arabian Cultural Mission
Query!
Address [1]
302766
0
16 Watson St, Turner ACT 2612
Australia
Query!
Country [1]
302766
0
Saudi Arabia
Query!
Primary sponsor type
University
Query!
Name
La Trobe University
Query!
Address
Plenty R0ad and Kingsbury Drive Bundoora VICTORIA 3086
Query!
Country
Australia
Query!
Secondary sponsor category [1]
302705
0
Hospital
Query!
Name [1]
302705
0
National Guard Health Affairs Hospital
Query!
Address [1]
302705
0
Ar Rimayah, Riyadh 14611, Saudi Arabia
Query!
Country [1]
302705
0
Saudi Arabia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
303363
0
La Trobe University Human Research Ethics Committee (HREC)
Query!
Ethics committee address [1]
303363
0
La Trobe University, Science Drive, Bundoora VICTORIA 3083
Building: David Myers East, Level 2, 224
Query!
Ethics committee country [1]
303363
0
Australia
Query!
Date submitted for ethics approval [1]
303363
0
16/05/2019
Query!
Approval date [1]
303363
0
27/06/2019
Query!
Ethics approval number [1]
303363
0
Query!
Summary
Brief summary
Type two diabetes is one of the fastest growing chronic diseases worldwide. Patients with type 2 diabetes must be committed to a daily routine to avoid diabetes complications. One of the problems they face is poor medication adherence. In this study we will test the feasability of Adherence Therapy which aims to help people to manage their medication more effectively. The therapy has not been tested among these patients. The objective of this study is to establish the feasibility of conducting Adherence Therapy in the Middle Eastern context.
This is a randomized and unblinded study that aims to establish the feasibility of conducting Adherence Therapy in the Middle Eastern context.
We aim to recruit 40 patients with diabetes. Patients who meet the eligibility criteria and provide consent will be randomly assigned into treatment as usual or Adherence Therapy.
Randomization will be via the sealed envelope website (www.sealedenvelope.com). The online randomization website generates random allocation sequence. To prevent selection bias, randomization will take place after the baseline measures have been completed. Allocation won’t be concealed.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
93410
0
Prof Richard Gray
Query!
Address
93410
0
La Trobe University
Plenty Rd & Kingsbury Dr,
George Singer Building, Level 3,
Bundoora, VIC 3086
Query!
Country
93410
0
Australia
Query!
Phone
93410
0
+61 (0)481248182
Query!
Fax
93410
0
Query!
Email
93410
0
[email protected]
Query!
Contact person for public queries
Name
93411
0
Mrs Fatimah Alenazi
Query!
Address
93411
0
La Trobe University
Plenty Rd & Kingsbury Dr,
George Singer Building, Level 3,
Bundoora, VIC 3086
Query!
Country
93411
0
Australia
Query!
Phone
93411
0
+61 0413399008
Query!
Fax
93411
0
Query!
Email
93411
0
[email protected]
Query!
Contact person for scientific queries
Name
93412
0
Prof Richard Gray
Query!
Address
93412
0
La Trobe University
Plenty Rd & Kingsbury Dr,
George Singer Building, Level 3,
Bundoora, VIC 3086
Query!
Country
93412
0
Australia
Query!
Phone
93412
0
+61394796743
Query!
Fax
93412
0
Query!
Email
93412
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual-level data - demographics and all clinical outcomes - will be made available. We will also make a data dictionary available.
Query!
When will data be available (start and end dates)?
Immediately following the award of Ph.D. no end date
Query!
Available to whom?
Anyone who wishes can access the data set
Query!
Available for what types of analyses?
Any purpose
Query!
How or where can data be obtained?
Unrestricted access via figshare https://latrobe.figshare.com/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Adherence therapy for adults with type 2 diabetes: a feasibility study of a randomized controlled trial.
2023
https://dx.doi.org/10.1186/s40814-023-01294-2
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF